People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

The move expands access to the novel mental health treatment, which has shown rapid symptom improvement for the past few ...